Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 07:30 ET | Source: Zevra Therapeutics

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

CELEBRATION, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living...
December 02, 2025 07:00 ET | Source: Ovid Therapeutics Inc.

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need,...
December 01, 2025 11:10 ET | Source: Research and Markets

European Association for the Study of Diabetes (EASD) Annual Meeting Highlights 2025: Advancements in GLP-1RAs for Diabetes, Cardiovascular Treatments, and Therapies for Resistant Hypertension

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "European Association for the Study of Diabetes (EASD): Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering.The...
December 01, 2025 08:00 ET | Source: Precedence Research

Targeted Drugs for Allergic Diseases Market Set to Hit USD 30.22 Billion by 2034, Driven by Rising Allergic Disorders

Ottawa, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The global targeted drugs for allergic diseases market size is calculated at USD 15.08 billion in 2025 and is expected to reach around USD 30.22 billion by...
December 01, 2025 07:30 ET | Source: Altimmune, Inc

Altimmune Announces CEO Transition and Succession Plan

Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.
December 01, 2025 07:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150...
December 01, 2025 07:00 ET | Source: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
December 01, 2025 07:00 ET | Source: Tessera Therapeutics

Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150...
November 28, 2025 00:28 ET | Source: SNS Insider pvt ltd

Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Atopic Dermatitis Drugs Market Size & Growth Analysis According to by SNS Insider, the Atopic Dermatitis Drugs Market size was valued at USD 14.93...
November 27, 2025 08:00 ET | Source: Sanofi Winthrop Industrie

Communiqué de presse : Sanofi investit 50 millions d’euros au Trait pour accélérer la production de médicaments innovants

Sanofi investit 50 millions d’euros au Trait pour accélérer la production de médicaments innovants Paris, France, 27 novembre 2025 – Sanofi inaugure aujourd’hui sur son site industriel du Trait, en...